一个整合尖端皮质电路建模和基于模拟的推理的框架,以检测阿尔茨海默病中皮质功能障碍的生物标志物
Marta Cárdenas Sánchez1, Alejandro Orozco Valero1, Juan Miguel García1
1Research Centre for Information and Communications Technologies (CITIC), University of Granada, 18014, Granada, Spain.
Interdisciplinary sciences, computational life sciences
|February 27, 2026
概括
这项研究引入了一个计算框架,使用脑电图 (EEG) 和机械建模来识别阿尔茨海默病 (AD) 生物标志物. 这些发现揭示了阿尔茨海默病患者的渐进性皮质功能障碍,有助于诊断和治疗的发展.
科学领域:
- 计算神经科学是一种计算神经科学.
- 神经成像生物标记物
- 阿尔茨海默病的研究研究.
背景情况:
- 皮层电路失衡为阿尔茨海默病 (AD) 提供了机械的洞察力.
- 确定可靠的神经成像生物标志物对于AD诊断和治疗至关重要.
研究的目的:
- 开发一个集成机械建模和基于模拟的推理 (SBI) 的计算框架,用于AD生物标志物发现.
- 通过使用脑电图 (EEG) 来识别AD皮质电路功能障碍的候选神经影像生物标志物.
主要方法:
- 一个尖的皮质电路模型产生了200万次模拟,以产生现实的EEG信号.
- 提取了EEG特征,并用于训练SBI模型来预测皮质参数.
- 该框架应用于各种疾病阶段的阿兹海默症患者的真实EEG数据.
主要成果:
- 多特征SBI模型在预测皮质参数方面表现出比单特征方法更高的准确性.
- 在阿尔茨海默病患者中发现了明显的皮质功能障碍模式,包括皮质-皮质连接性降低.
- 在晚期的AD阶段观察到一个减少的激发时间常数,表明向抑制转移.
结论:
- 计算框架提供了一个可扩展和可解释的方法,用于将大脑模型与神经成像联系起来.
- 在AD中可以确定皮质功能障碍的生理学上有意义的生物标志物.
- 通过EEG分析,这些发现有助于更好地理解和潜在地诊断AD.
相关概念视频
Neural Circuits
Neural circuits and neuronal pools are two of the main structures found in the nervous system. Neural circuits are networks of neurons that work together to carry out a specific task or process. They consist of interconnected neurons and glial cells, which provide structural and metabolic support.
Neuronal pools are collections of nerve cells with similar functions and interact through chemical and electrical signals. These pools include both interneurons (the central neural circuit nodes that...
Neuronal pools are collections of nerve cells with similar functions and interact through chemical and electrical signals. These pools include both interneurons (the central neural circuit nodes that...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...


